Sermorelin vs Ipamorelin vs CJC-1295: Compared
Sermorelin, CJC-1295 and Ipamorelin are routinely grouped together under the heading of growth hormone secretagogues, and that grouping obscures more than it explains. Two of the three act at one receptor; the third acts at a completely different one. Their circulating half-lives differ by roughly three orders of magnitude. The research questions each compound was originally designed to answer are not the same. This article separates them.
What follows describes documented laboratory and pharmacological characteristics only. It does not describe or endorse any human or veterinary use.
Two receptors, not three compounds
Growth hormone release from the anterior pituitary is governed by two opposing hypothalamic signals — growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which suppresses it. The interplay between the two produces the pulsatile secretion pattern that characterises somatotroph activity. A third input, the endogenous ligand ghrelin, acts at a separate receptor to amplify release.
The three compounds under discussion divide cleanly along that anatomy.
The GHRH receptor pathway
Sermorelin and CJC-1295 are both GHRH analogues. They bind the GHRH receptor, a class B G-protein-coupled receptor expressed on pituitary somatotrophs, and signal through the cAMP–protein kinase A cascade. Because they operate through the native GHRH pathway, the resulting release remains subject to somatostatin's inhibitory tone and to the normal negative feedback exerted by circulating IGF-1.
The ghrelin receptor pathway
Ipamorelin is not a GHRH analogue. It is an agonist at the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — which signals through the phospholipase C / inositol trisphosphate pathway rather than through cAMP. Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) family, alongside GHRP-2 and GHRP-6.
This is the single most useful distinction to hold onto. Comparing Sermorelin to Ipamorelin is not comparing two versions of the same thing; it is comparing two different receptor systems that happen to converge on the same cell type.
Sermorelin: the reference GHRH fragment
Sermorelin (CAS 86168-78-7) is GRF(1-29) amide — the first 29 residues of the 44-amino-acid human GHRH molecule, with a C-terminal amide modification. Its molecular formula is C149H246N44O42S, giving a molecular weight of approximately 3,358 g/mol.
The 1-29 fragment is significant because it is the shortest portion of GHRH that retains full biological activity at the receptor. Everything beyond residue 29 can be removed without loss of potency, which made GRF(1-29) the natural starting point for essentially every GHRH analogue developed since. Sermorelin has an established history as a diagnostic agent in endocrine research, where it has been used to probe pituitary somatotroph responsiveness.
Its defining pharmacokinetic feature is brevity. Sermorelin is cleared rapidly from circulation, with a plasma half-life conventionally cited in the range of ten to twelve minutes — a consequence of dipeptidyl peptidase-4 cleavage at the N-terminal Tyr-Ala bond and general proteolytic degradation. In research terms this is not necessarily a limitation: a short signal produces a discrete, measurable pulse rather than a sustained elevation, which is precisely what a diagnostic stimulation test requires.
CJC-1295: engineering a longer signal
CJC-1295 was developed by ConjuChem Biotechnologies as a direct answer to the clearance problem. Two separate strategies were applied to the same GRF(1-29) backbone.
The first was substitution. Four residues in the native sequence were replaced — D-Ala at position 2, Gln at position 8, Ala at position 15 and Leu at position 27 — producing what is often labelled "modified GRF(1-29)". The D-Ala2 substitution is the important one: it blocks DPP-4 cleavage at the primary degradation site, and the remaining substitutions reduce susceptibility to asparagine deamidation and trypsin-like cleavage. This tetrasubstituted analogue is what is generally supplied as CJC-1295 without DAC.
The second strategy was albumin conjugation. In the full DAC construct — formally Nε30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-Sermorelin-Lys30 (CAS 863288-34-0) — a thirtieth residue, lysine, is appended, and its side-chain amine carries a 3-maleimidopropionic acid group. The maleimide is a Michael acceptor that reacts selectively with Cys34 of human serum albumin, the most abundant free thiol in plasma, forming a covalent thioether conjugate. The peptide effectively becomes a passenger on a 66 kDa carrier protein and is removed from renal filtration.
What the DAC modification demonstrably does
The pharmacokinetic consequence was quantified in a randomised, double-blind, placebo-controlled study by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2006. The estimated terminal half-life of CJC-1295 was 5.8 to 8.1 days. Single subcutaneous administration produced dose-dependent increases in mean plasma GH of two- to ten-fold sustained for six days or more, and increases in IGF-1 of 1.5- to three-fold sustained for nine to eleven days. After repeated administration, IGF-1 remained above baseline for up to 28 days, indicating a cumulative effect.
That is a shift from roughly ten minutes to roughly a week — a change of about three orders of magnitude from the same 29-residue starting sequence. It also fundamentally changes what the compound models. Sermorelin produces a pulse; CJC-1295 with DAC produces a sustained elevation, sometimes described in the literature as a "bleed" rather than a pulse. Researchers investigating pulsatility and researchers investigating chronic receptor exposure are therefore studying different molecules for good reason, and the DAC / no-DAC distinction is not a trivial product variant.
Ipamorelin: selectivity as the design goal
Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, identified at Novo Nordisk and first characterised by Raun and colleagues in the European Journal of Endocrinology in 1998. It emerged from a chemistry programme built around GHRP-1 analogues lacking the central Ala-Trp dipeptide.
The problem Ipamorelin was designed to solve was not duration but specificity. Earlier GHRPs released growth hormone effectively, but they did not do so cleanly. In Raun's swine model, both GHRP-6 and GHRP-2 produced measurable increases in plasma ACTH and cortisol alongside GH — activation of the hypothalamic-pituitary-adrenal axis that confounds any experiment attempting to isolate somatotroph effects.
Ipamorelin did not. The 1998 paper reported that Ipamorelin released GH in conscious swine with an ED50 of 2.3 ± 0.03 nmol/kg and an Emax of 65 ± 0.2 ng/ml — comparable to GHRP-6 — while producing no increase in ACTH or cortisol distinguishable from that seen after GHRH stimulation. This held at doses more than 200-fold above the ED50 for GH release. None of the secretagogues tested altered FSH, LH, prolactin or TSH. The authors concluded that Ipamorelin was the first GHRP-receptor agonist with a selectivity for GH release comparable to GHRH itself.
That selectivity is the reason Ipamorelin remains widely used in research contexts where a clean ghrelin-receptor signal is required. Its half-life is short — on the order of two hours — so like Sermorelin it produces a discrete pulse rather than sustained exposure.
Why GHRH analogues and GHRPs are studied together
Because the two receptor systems are independent, their effects combine in a way that is greater than additive. Bowers and colleagues documented this synergy in the Journal of Clinical Endocrinology and Metabolism in 1990, showing that a growth hormone-releasing peptide administered together with GHRH produced GH release exceeding the sum of the individual responses. The finding has been reproduced across multiple models, including work by Cordido and colleagues in which combined GHRH and GHRP-6 administration produced markedly larger GH discharge than either agent alone.
The mechanistic explanation generally offered is that GHRP activity includes functional antagonism of somatostatin tone at the pituitary, while simultaneously acting through its own receptor. A GHRH analogue pushing on the accelerator while a GHRP eases off the brake produces a larger response than either intervention in isolation.
This is why a combined CJC-1295 and Ipamorelin preparation exists in research catalogues. It is not a packaging convenience; it reflects a genuine and well-documented pharmacological interaction between two distinct receptor pathways, and it is the configuration most often referenced in comparative work.
What this means for experimental design
Selection between these compounds follows from the research question rather than from any ranking of potency.
- Work concerned with acute pituitary responsiveness, or with reproducing a discrete GHRH-driven pulse, most often references Sermorelin — the short half-life is the feature, not a drawback.
- Work concerned with sustained GHRH-receptor exposure, IGF-1 kinetics over days, or cumulative effects references CJC-1295 with DAC, for which published half-life data is available.
- Work concerned specifically with the ghrelin-receptor pathway, and requiring that adrenal-axis activation be excluded as a confounder, references Ipamorelin, on the strength of the selectivity data from Raun 1998.
- Work examining pathway synergy uses a GHRH analogue and a GHRP together, which is the basis of the combined preparations.
A common source of confusion in the secondary literature is the CJC-1295 naming problem. "CJC-1295" without qualification may refer either to the DAC conjugate or to the unconjugated tetrasubstituted GRF(1-29). These have entirely different pharmacokinetic profiles — days versus roughly half an hour — and any dataset that does not specify which was used is difficult to interpret. Confirming which construct a given vial contains is a basic prerequisite for reproducible work.
Handling considerations
All three are supplied lyophilised and require reconstitution before use, with bacteriostatic water the conventional diluent for multi-draw work. All three should be stored cold and protected from light in both powder and solution form, and none requires special handling relative to the others. Ipamorelin, as a pentapeptide, is the most structurally robust of the three; the 29- and 30-residue GHRH analogues are more susceptible to aggregation and to degradation from freeze-thaw cycling, so aliquoting reconstituted solution rather than repeatedly thawing a single vial is standard practice.
Verification
Because these compounds are structurally related — CJC-1295 is a substituted derivative of the same backbone as Sermorelin — identity confirmation matters more here than it does for unrelated molecules. A four-residue substitution, or the presence or absence of a maleimidopropionyl group, produces a mass difference that HPLC retention time alone may not resolve unambiguously. Mass spectrometry is the appropriate confirmation method.
All compounds in our catalogue are independently analysed by third-party laboratory using HPLC-MS, with batch-specific Certificates of Analysis published on our Lab Results page, including the chromatogram for the batch supplied.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.